Evidence map›Paper›PMID 41764626›Full record

ArticleCurrent pharmaceutical design2026

Pankaj Verma, Sanjeev Kumar Sahu, Ravi Rawat, Volkan Eyupoglu, Preeti Patel, Palwinder Kaur, Pratibha Pandey, Manish Vyas

Abstract read
PubMed Publisher
In one paragraph

Article in Current pharmaceutical design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Pankaj VermaSchool of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India.
Sanjeev Kumar SahuSchool of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India.
Ravi RawatSchool of Health Sciences & Technology, University of Petroleum and Energy Studies, UPES University, Dehradun, 248007, India.
Volkan EyupogluDepartment of Chemistry, Cankırı Karatekin University, Cankırı, 18100, Turkey.
Preeti PatelISF College of Pharmacy, Moga, Punjab, 142001, India.
Palwinder KaurSchool of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India.
Pratibha PandeyCentre for Research Impact and Outcome, Chitkara University Institute of Engineering and Technology, Chitkara University, Rajpura, 140401, Punjab, India.
Manish VyasSchool of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionHypertension is a major global health concern, and the exploration of natural compounds as potential antihypertensive agents has been a recent area of study. The ancient medicinal tree Terminalia arjuna is very potent for treating cardiovascular conditions. Its bark is rich in bioactive compounds, such as flavonoids, tannins, and triterpenoids, which exhibit cardioprotective properties.

methodsThis research focused on identifying and characterizing antihypertensive phytoconstituents of Terminalia arjuna through molecular docking, dynamic simulations, and DFT studies. We systematically screened bioactive compounds from the plant for their ability to interact with key targets (PDB:2X96), which are involved in the regulation of blood pressure using AutoDock Tools 1.5.7. The dynamic behavior of the complexes was evaluated using molecular dynamics (MD) simulation in the GROMACS package program (version 2022.2). DFT calculations were performed using DMol3 (Discovery Studio Client) to determine molecular electronic properties.

resultsWe identified Quercetin and Ellagic acid as promising ligands with strong binding affinities and significant pre-ADMET analysis database. Further, molecular dynamics simulations (500 ns) provided insights into the stability and binding modes of these selected compounds, highlighting their potential for long-term efficacy. DFT calculations were employed to evaluate the electronic properties, such as frontier molecular orbital analysis and electrostatic potential mapping, revealing the reactivity and interaction profiles of the compounds. The docking scores and MMGBSA binding free energy value of Ellagic acid with AnCE-RXPA380 complex target protein were found to be -9.5 and -17.94 kcal/mol, respectively, which is higher as compared to Captopril (--5.7 and --4.36 kcal/mol kJ/mol). DISCUSSION: Ellagic acid exhibits more conventional hydrogen binding efficiency at 2X96 receptor with GLN A:361, THR A:364, ASP A:360, LYS A:495, and GLN A:265, respectively, providing a scientific basis for its use in hypertension management Furthermore.

conclusionOur results suggest that Ellagic acid from Terminalia arjuna possesses significant antihypertensive potential due to the highest binding efficiency with 2X96 receptor. However, in vitro, and in vivo experimentation are needed to validate the antihypertensive potential of Ellagic acid in the future.

Indexed as

Antihypertensive AgentsDensity Functional TheoryMolecular Docking SimulationMolecular Dynamics SimulationPhytochemicalsPlant ExtractsTerminaliaHumansMolecular StructureAntihypertensive AgentsPhytochemicalsPlant ExtractsantihypertensiveDFTInsulinmolecular dynamicsphytoconstituentsTerminalia arjuna

Identifiers

PMID41764626

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.